K-912

K-912 is an investigational antitumor antibiotic-type agent being developed by Kowa for the treatment of advanced solid tumors. Administered intravenously, K-912 belongs to a class of cytotoxic compounds that typically exert their effect by binding to or alkylating DNA, which leads to the inhibition of DNA synthesis and the induction of cell death in malignant tissues. The drug is currently in early-phase clinical development, with a Phase 1 dose-escalation study underway in Japan to evaluate its safety, tolerability, and pharmacokinetics in patients with advanced solid tumors that are refractory to standard therapies.